Inverness gets US antitrust green light for Cholestech buy:
This article was originally published in Clinica
Executive Summary
US antitrust authorities have approved Inverness Medical Innovations' proposed acquisition of heart disease diagnostics company Cholestech. Waltham, Massachusetts-based Inverness agreed to buy Cholestech in a stock-for-stock merger, where each Cholestech share is exchanged for 0.43642 Inverness shares (see Clinica No 1259, p 18). The transaction is slated to close in the third quarter of 2007.